REFERENCES
1. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864-84.
2. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology. 2011;54:1998-2004.
3. Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77:128-39.
4. Agarwal PD, Phillips P, Hillman L, et al. Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival. J Clin Gastroenterol. 2017;51:845-9.
5. Seif El Dahan K, Reczek A, Daher D, et al. Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. Hepatol Commun. 2023;7:e0143.
6. Sinn DH, Choi GS, Park HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730.
7. Giannini EG, Pieri G, Plaz Torres MC. Towards an integrated management model for hepatocellular carcinoma. Dig Liver Dis. 2024;56:2022-4.
8. Trevisani F, De Notariis S, Rapaccini G, et al; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734-44.
9. Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
10. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
11. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-70.
12. Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28:583-705.
13. Hasegawa K, Takemura N, Yamashita T, et al; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383-90.
14. Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res. 2021;51:1013-25.
15. Burak KW, Sherman M. Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian association for the study of the liver hepatocellular carcinoma meeting. Can J Gastroenterol Hepatol. 2015;29:178-84.
16. Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8:e101.
17. Singal AG, Patibandla S, Obi J, et al. Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis. Clin Gastroenterol Hepatol. 2021;19:1925-32.e1.
18. Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017;Epub ahead of print.
19. Park J, Le AK, Tseng TC, et al. Progression rates by age, sex, treatment, and disease activity by AASLD and EASL criteria: data for precision medicine. Clin Gastroenterol Hepatol. 2022;20:874-85.e4.
20. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800-6.
21. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954-61.
22. Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444-53.
23. Carrat F, Fontaine H, Dorival C, et al; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453-64.
24. Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology. 2022;76:139-54.
25. Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021;74:458-65.
26. Kim NJ, Vutien P, Berry K, Ioannou GN. Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after hepatitis c virus cure with direct-acting antivirals in patients with cirrhosis or high fibrosis-4 score. Gastroenterology. 2022;163:1104-6.e3.
27. Izzo F, Piccirillo M, Albino V, et al. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB. 2013;15:985-90.
28. Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C in the era of direct-acting antiviral agents. JAMA Netw Open. 2020;3:e2021173.
29. Ganne-Carrié N, Chaffaut C, Bourcier V, et al; for CIRRAL Group. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274-83.
30. Heckley GA, Jarl J, Asamoah BO, G-Gerdtham U. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer. 2011;11:446.
31. Tan DJH, Tamaki N, Kim BK, et al; Global Liver Cancer Consortium. Prevalence of low FIB-4 in MASLD-related hepatocellular carcinoma: a multicentre study. Aliment Pharmacol Ther. 2025;61:278-85.
32. Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75:1476-84.
33. Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin. 2020;36:235-43.
34. Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol. 2021;19:806-15.e5.
35. Lee HW, Kim KH, Ahn SH, Lee HC, Choi J. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease. Liver Int. 2024;44:1448-55.
36. Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74:775-82.
37. Ding H, Tu H, Qu C, et al; Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Committee of Hepatology of Chinese Research Hospital Association, Hepatology Society of Chinese Medical Association, Prevention of Infection Related Cancer (PIRCA) Group, Specialist Committee of Cancer Prevention and Control of Chinese Preventive Medicine Association. Guideline for stratified screening and surveillance in patients with high risk of primary liver cancer (2020). HR. 2021;7:17.
38. Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
39. Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65:1196-205.
40. Narasimman M, Hernaez R, Cerda V, et al. Financial burden of hepatocellular carcinoma screening in patients with cirrhosis. Clin Gastroenterol Hepatol. 2024;22:760-7.e1.
41. Narasimman M, Hernaez R, Cerda V, et al. Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis. Hepatology. 2024;79:107-17.
42. Curran C, Priest M, Datta S, Forrest EH, Stanley AJ, Barclay ST. Hepatocellular carcinoma risk scores predict patients under surveillance at low risk of benefit and high risk of harm. Dig Dis Sci. 2023;68:770-7.
43. Suddle A, Reeves H, Hubner R, et al. British society of gastroenterology guidelines for the management of hepatocellular carcinoma in adults. Gut. 2024;73:1235-68.
44. Del Poggio P, Olmi S, Ciccarese F, et al; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1927-33.e2.
45. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018;24:1171-7.
46. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706-18.e1.
47. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25:1550-9.
48. Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-5.
49. Giannini EG, Sammito G, Farinati F, et al; Italian Liver Cancer (ITA.LI.CA) Group. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer. 2014;120:2150-7.
50. Vipani A, Lauzon M, Luu M, Roberts LR, Singal AG, Yang JD. Decreasing trend of serum α-fetoprotein level in hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2022;20:1177-9.e4.
51. Qian X, Liu S, Long H, et al. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat. 2021;28:20-9.
52. Gopal P, Yopp AC, Waljee AK, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:870-7.
53. Biselli M, Conti F, Gramenzi A, et al. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer. 2015;112:69-76.
54. Tayob N, Stingo F, Do KA, Lok ASF, Feng Z. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics. 2018;74:249-59.
55. Parikh ND, Tayob N, Al-Jarrah T, et al. Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort. JAMA Netw Open. 2022;5:e2223504.
56. Zhao C, Jin M, Le RH, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 2018;38:503-14.
57. Toyoda H, Yasuda S, Shiota S, Kumada T, Tanaka J. Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response. Eur J Gastroenterol Hepatol. 2022;34:693-7.
58. Rao A, Rich NE, Marrero JA, Yopp AC, Singal AG. Diagnostic and therapeutic delays in patients with hepatocellular carcinoma. J Natl Compr Canc Netw. 2021;19:1063-71.
59. Govalan R, Luu M, Lauzon M, et al. Therapeutic underuse and delay in hepatocellular carcinoma: prevalence, associated factors, and clinical impact. Hepatol Commun. 2022;6:223-36.
60. Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016;14:875-86.e6.
61. Fujiwara N, Lopez C, Marsh TL, et al. Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis. Gastroenterology. 2025;168:556-67.e7.
62. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-61.
63. Marsh TL, Parikh ND, Roberts LR, et al. A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis. Gastroenterology. 2025;168:316-26.e6.
64. Singal AG, Parikh ND, Kanwal F, et al. National liver cancer screening trial (TRACER) study protocol. Hepatol Commun. 2024;8:e0565.
65. Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era? J Hepatol. 2023;78:207-16.
66. Park HJ, Jang HY, Kim SY, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. J Hepatol. 2020;72:718-24.
67. Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021;75:108-19.
68. Giannini EG. Proper assessment and prognostication of patients with hepatocellular carcinoma. Clin Liver Dis. 2024;23:e0129.
69. Nahon P, Najean M, Layese R, et al; ANRS CO12 CirVir, ANRS CO22 Hepather, Scientific Committee - Voting members, CIRRAL groups. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Rep. 2021;4:100390.
70. Kao SZ, Sangha K, Fujiwara N, Hoshida Y, Parikh ND, Singal AG. Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis. EClinicalMedicine. 2024;75:102755.
71. Farhang Zangneh H, Wong WWL, Sander B, et al. Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis. Clin Gastroenterol Hepatol. 2019;17:1840-9.e16.
72. Lani L, Stefanini B, Trevisani F. Surveillance for hepatocellular carcinoma in patients with successfully treated viral disease of the liver: a systematic review. Liver Cancer. 2024;13:376-88.
73. Chhatwal J, Hajjar A, Mueller PP, et al. Hepatocellular carcinoma incidence threshold for surveillance in virologically cured hepatitis C individuals. Clin Gastroenterol Hepatol. 2024;22:91-101.e6.
74. EASLTM The Home of Hepatology. EASL policy statement: risk-based surveillance for hepatocellular carcinoma among patients with cirrhosis. Available from: https://easl.eu/publication/easl-policy-statement-risk-based/. [Last accessed on 11 Mar 2025].
75. Lim YX, Lim ZL, Ho PJ, Li J. Breast cancer in Asia: incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. Cancers. 2022;14:4218.
76. Ronot M, Nahon P, Rimola J. Screening of liver cancer with abbreviated MRI. Hepatology. 2023;78:670-86.
77. Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer. 2018;7:134-47.
78. Shiha G, Hassan A, Mousa N, et al. Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR: prospective study. Aliment Pharmacol Ther. 2025;61:99-108.
79. Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of hepatocellular carcinoma risk following HCV eradication or HBV control. J Clin Med. 2021;10:353.
80. Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: is it time to personalize it? World J Gastroenterol. 2021;27:5536-54.
81. Tobari M, Hashimoto E, Taniai M, et al. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35:862-9.
82. Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DT. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022;28:96-107.
83. Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120:3485-93.
84. Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-85.
85. Azzi J, Dorival C, Cagnot C, et al; ANRS-AFEF Hepather Study group. Prediction of hepatocellular carcinoma in hepatitis C patients with advanced fibrosis after sustained virologic response. Clin Res Hepatol Gastroenterol. 2022;46:101923.
86. Semmler G, Meyer EL, Kozbial K, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2022;76:812-21.
87. Yang HI, Yeh ML, Wong GL, et al. Real-world effectiveness from the Asia Pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy. J Infect Dis. 2020;221:389-99.
88. Nardone V, Marmorino F, Germani MM, et al. The role of artificial intelligence on tumor boards: perspectives from surgeons, medical oncologists and radiation oncologists. Curr Oncol. 2024;31:4984-5007.
